Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Public ClinicalTrials.gov record NCT04750226. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
Study identification
- NCT ID
- NCT04750226
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 118 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 18, 2021 (Actual)
- Primary completion
- Apr 27, 2026 (Actual)
- Completion
- Apr 27, 2026 (Actual)
- Last update posted
- Jun 1, 2026
2021 – 2026
United States locations
- U.S. sites
- 47
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 217814 | Birmingham | Alabama | 35233 | — |
| Usa Mitchell Cancer Institute /ID# 218467 | Mobile | Alabama | 36604 | — |
| Xenoscience, Inc /ID# 222515 | Phoenix | Arizona | 85004 | — |
| Muhammad Ali Parkinson Center /ID# 218609 | Phoenix | Arizona | 85013-4407 | — |
| Movement Disorders Center of Arizona /ID# 218471 | Scottsdale | Arizona | 85258-4582 | — |
| Neuro Pain Research Center /ID# 217720 | Fresno | California | 93710 | — |
| Loma Linda University Medical /ID# 217724 | Loma Linda | California | 92354 | — |
| University of California, Los Angeles /ID# 218460 | Los Angeles | California | 90095 | — |
| SC3 Research Group - Pasadena /ID# 223018 | Pasadena | California | 91105-3149 | — |
| University of California, San /ID# 218595 | San Diego | California | 92037 | — |
| Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 218607 | West Hollywood | California | 90048 | — |
| University of Colorado Hospital /ID# 218486 | Aurora | Colorado | 80045 | — |
| Alpine Clinical Research Center /ID# 218461 | Boulder | Colorado | 80301-1880 | — |
| Denver Neurological Research, LLC /ID# 217811 | Denver | Colorado | 80210-7009 | — |
| CenExel Rocky Mountain Clinical Research, LLC /ID# 217731 | Englewood | Colorado | 80113-2736 | — |
| Georgetown University Hospital /ID# 218599 | Washington D.C. | District of Columbia | 20007 | — |
| Visionary Investigators Network - Miami /ID# 217726 | Miami | Florida | 33176-2148 | — |
| Renstar Medical Research /ID# 217837 | Ocala | Florida | 34470 | — |
| Neurology Associates Ormond Beach /ID# 217800 | Ormond Beach | Florida | 32174 | — |
| Parkinson's Disease Treatment Center of Southwest Florida /ID# 222679 | Port Charlotte | Florida | 33980 | — |
| University of South Florida- Neuroscience Institute /ID# 218481 | Tampa | Florida | 33613 | — |
| Premiere Research Institute - Palm Beach /ID# 218743 | West Palm Beach | Florida | 33407-3209 | — |
| Rush University Medical Center /ID# 217807 | Chicago | Illinois | 60612 | — |
| University of Chicago Medical Center /ID# 218611 | Chicago | Illinois | 60637 | — |
| St Elizabeth's Medical Center - Brighton /ID# 223082 | Brighton | Massachusetts | 02135-2907 | — |
| St. Lukes Hosp. of Kansas City /ID# 218604 | Kansas City | Missouri | 64111 | — |
| Washington University-School of Medicine /ID# 217723 | St Louis | Missouri | 63110 | — |
| Global Neurosciences Institute /ID# 218472 | Lawrenceville | New Jersey | 08648-2300 | — |
| Northwell Health /ID# 218600 | Lake Success | New York | 11042 | — |
| M3 Wake Research - Raleigh /ID# 218482 | Raleigh | North Carolina | 27612-8106 | — |
| The Orthopedic Foundation /ID# 218608 | New Albany | Ohio | 43054-8167 | — |
| The Movement Disorder Clinic of Oklahoma /ID# 218580 | Tulsa | Oklahoma | 74136-6378 | — |
| Legacy Medical Group - Neurology /ID# 217804 | Portland | Oregon | 97232-2003 | — |
| University of Pennsylvania /ID# 218605 | Philadelphia | Pennsylvania | 19104-5502 | — |
| Thomas Jefferson University Hospital /ID# 218594 | Philadelphia | Pennsylvania | 19107 | — |
| Prisma Health-Upstate /ID# 217803 | Greenville | South Carolina | 29615 | — |
| Coastal Neurology /ID# 222893 | Port Royal | South Carolina | 29935-2029 | — |
| KCA Neurology - Franklin /ID# 222811 | Franklin | Tennessee | 37067-5914 | — |
| Vanderbilt University Medical Center /ID# 217722 | Nashville | Tennessee | 37232-0011 | — |
| St. David's Healthcare Partnership, L.P., LLP /ID# 248148 | Austin | Texas | 78701-4082 | — |
| Houston Pulmonary Sleep and Allergy Associates /ID# 218473 | Cypress | Texas | 77429 | — |
| Texas Movement Disorder Specialists /ID# 218610 | Georgetown | Texas | 78628-4126 | — |
| Baylor College of Medicine /ID# 217728 | Houston | Texas | 77030 | — |
| University of Utah Health Care /ID# 218597 | Salt Lake City | Utah | 84132 | — |
| Neurological Associates - Forest Ave /ID# 218458 | Richmond | Virginia | 23229-4913 | — |
| Inland Northwest Research /ID# 222520 | Spokane | Washington | 99202-1342 | — |
| Duplicate_Medical College of Wisconsin /ID# 217721 | Milwaukee | Wisconsin | 53226-3522 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04750226, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04750226 live on ClinicalTrials.gov.